BioNTech SE (BNTX) EBITDA Margin: -9.29%
Is BioNTech SE’s EBITDA margin high or low?
BioNTech SE's EBITDA margin of -9.29% is 138% below its 5-year average of 24.39%, near the low end of its 5-year range (-21.79%–79.06%).
The EBITDA margin for BioNTech SE (BNTX) is -9.29% as of Wednesday, June 10, 2026. It is above its 12-month average by 17.90% (-11.31%).
BNTX EBITDA Margin Chart
BNTX Average EBITDA Margin Chart
BNTX Current vs Average EBITDA Margin Chart
BNTX EBITDA Margin Metrics
EBITDA MARGIN
-9.29%
EBITDA MARGIN AVG TTM
-11.31%
EBITDA MARGIN AVG 3Y
22.27%
EBITDA MARGIN AVG 5Y
24.39%
EBITDA MARGIN AVG 10Y
-14.01%
EBITDA MARGIN AVG 15Y
-14.01%
EBITDA MARGIN AVG 20Y
-14.01%
CURRENT VS TTM AVG
+17.90%
CURRENT VS 3Y AVG
-141.71%
CURRENT VS 5Y AVG
-138.08%
CURRENT VS 10Y AVG
+33.70%
CURRENT VS 15Y AVG
+33.70%
CURRENT VS 20Y AVG
+33.70%
BNTX Competitors' EBITDA Margin
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BioNTech SE (BNTX) | — | -9.29% | -11.31% | 22.27% | 24.39% |
| Mettler-Toledo International Inc. (MTD) | $22.85B | 30.67% | 31.14% | 31.31% | 30.59% |
| Waters Corporation (WAT) | $23.83B | 31.97% | 33.50% | 33.77% | 33.93% |
| Moderna, Inc. (MRNA) | $18.40B | -131.33% | -118.72% | -58.41% | -40.82% |
| Hologic, Inc. (HOLX) | $16.97B | 24.97% | 28.56% | 32.04% | 36.42% |
| Veeva Systems Inc. (VEEV) | $27.37B | 28.68% | 27.64% | 24.37% | 25.68% |
| Biogen Inc. (BIIB) | $29.00B | 31.60% | 31.28% | 30.38% | 32.54% |
| DexCom, Inc. (DXCM) | $29.24B | 24.96% | 24.20% | 23.29% | 21.36% |
| IQVIA Holdings Inc. (IQV) | $30.60B | 21.24% | 21.82% | 21.39% | 20.63% |
| Align Technology, Inc. (ALGN) | $12.56B | 18.98% | 19.70% | 20.24% | 21.31% |
Margin Comparison
Gross Margin
73.3%
EBITDA Margin
-9.3%
Operating Margin
-51.5%
Net Margin
-44.7%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
- Removes effects of depreciation policies (D&A)
- Capital structure neutral (ignores interest)
- Tax neutral (ignores tax differences)
- Good proxy for operating cash generation
BioNTech SE EBITDA Margin Formula & Definition
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
BioNTech SE EBITDA Margin FAQ
- What is the EBITDA margin for BioNTech SE (BNTX)?
- The EBITDA margin for BNTX stock is -9.29%.
- Is BioNTech SE's EBITDA margin high or low?
- BioNTech SE's EBITDA margin of -9.29% is 138% below its 5-year average of 24.39%, near the low end of its 5-year range (-21.79%–79.06%).
- What is the TTM average EBITDA margin for BioNTech SE (BNTX)?
- The TTM average EBITDA margin for BNTX stock is -11.31%.
- What is the 3Y average EBITDA margin for BioNTech SE (BNTX)?
- The 3Y average EBITDA margin for BNTX stock is 22.27%.
- What is the 5Y average EBITDA margin for BioNTech SE (BNTX)?
- The 5Y average EBITDA margin for BNTX stock is 24.39%.
- What is the 10Y average EBITDA margin for BioNTech SE (BNTX)?
- The 10Y average EBITDA margin for BNTX stock is -14.01%.
- What is the 15Y average EBITDA margin for BioNTech SE (BNTX)?
- The 15Y average EBITDA margin for BNTX stock is -14.01%.
- What is the 20Y average EBITDA margin for BioNTech SE (BNTX)?
- The 20Y average EBITDA margin for BNTX stock is -14.01%.
BioNTech SE EBITDA Margin History
| DATE | EBITDA MARGIN |
|---|---|
| 2025-12-31 | -9.29% |
| 2024-12-31 | -13.34% |
| 2023-12-31 | 36.07% |
| 2022-12-31 | 75.65% |
| 2021-12-31 | 79.06% |
| 2020-12-31 | -21.79% |
| 2019-12-31 | -132.41% |
| 2018-12-31 | -18.78% |
| 2017-12-31 | -121.27% |
Related Metrics
About BioNTech SE
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ugur Sahin